Multicenter Randomized, Double-blind, Placebo-controlled Parallel Clinical Trial to Assess Efficacy and Safety of Omalizumab (Xolair) in a New Indication: Cholinergic Urticarial
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 24 Jun 2017 Status changed from active, no longer recruiting to completed.
- 01 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Jan 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.